Clinical results of EGFR-targeted therapies in advanced colorectal cancer

This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.